Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2401 to 2415 of 8903 results

  1. Spartan RX point-of-care CYP2C19 test

    Topic prioritisation

    Diagnostics guidance
    Topic prioritisation

  2. Healthy.io test for home testing of urine albumin to creatinine ratio

    Topic prioritisation

    Diagnostics guidance
    Topic prioritisation

  3. FebriDx for C-reactive protein and myxovirus resistance protein A testing

    Topic prioritisation

    Diagnostics guidance
    Topic prioritisation

  4. Helge for detecting haemolysis

    Topic prioritisation

    Diagnostics guidance
    Topic prioritisation

  5. NATROX oxygen wound therapy for managing diabetic foot ulcers and complex or chronic non-healing wounds

    Topic prioritisation

    Medical technologies guidance
    Topic prioritisation

  6. Rezafungin for untreated invasive candidiasis [TSID10768]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  7. Dulaglutide for treating type 2 diabetes in children and young people [TSID10660]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  8. ABP 959 (eculizumab biosimilar) for treating paroxysmal nocturnal haemoglobinuria [TSID10250]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  9. DV7103 for treating cystinuria in people 6 months and over [TSID10438]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  10. ABP-654 (ustekinumab biosimilar) for previously treated moderate to severe plaque psoriasis [TSID11790]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  11. Macitentant–tadalafil for treating pulmonary arterial hypertension [TSID10517]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  12. Ivacaftor for treating cystic fibrosis with mutations in the CFTR gene in babies and children aged 1 to 3 months or weighing 3 kg to 24 kg [TSID11894]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  13. Elexacaftor–tezacaftor–ivacaftor and ivacaftor for treating cystic fibrosis with at least 1 F508del mutation in the CFTR gene in children aged 2 to 5 [TSID10767]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  14. Ceftobiprole medocaril for treating community- or hospital-acquired pneumonia in people 3 months to 17 years [TSID11819]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  15. Aflibercept for untreated diabetic macular oedema [TSID10621]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation